Notice of Results and Online Investor Presentation

RNS Number : 3570E
Accrol Group Holdings PLC
07 July 2021
 

7 July 2021

 

ACCROL GROUP HOLDINGS PLC
("Accrol" or the "Group")

AIM: ACRL

 

Notice of Results and Online Investor Presentation

 

Accrol Group, one of the UK's leading independent tissue converters, announces that it will release its Final Results for the year ended 30 April 2021 on Wednesday, 14 July 2021.

 

An analyst briefing will be held online at 9.00 am on that day. Equity analysts interested in joining the meeting should contact Belvedere Communications, see details below.

 

As part of the Group's Final Results roadshow, the management will host an online investor presentation and Q&A session. This will take place on Thursday, 15 July 2021 at 1.15pm. Anyone wishing to participate should register for the event with PI World at: https://bit.ly/ACRL_FY21_webinar.

 

 

For further information, please contact:




Accrol Group Holdings plc


Dan Wright, Executive Chairman

Via Belvedere Communications

Gareth Jenkins, Chief Executive Officer




Zeus Capital Limited (Nominated Adviser & Broker) 


Dan Bate / Jordan Warburton

Tel: +44 (0) 161 831 1512

Dominic King / John Goold

Tel: +44 (0) 203 829 5000



Liberum Capital Limited (Joint Broker)

Tel: +44 (0) 20 3100 2222

Clayton Bush / Edward Thomas




Belvedere Communications Limited


Cat Valentine

Tel: +44 (0) 7715 769 078

Keeley Clarke

Tel: +44 (0) 7967 816 525


accrolpr@belvederepr.com

 

Overview of Accrol

 

Accrol Group Holdings plc is a leading tissue converter and supplier of toilet tissues, kitchen rolls and facial tissues to many of the UK's leading discounters and grocery retailers across the UK. Following the recent acquisition of a state-of-the-art tissue converter based in Leicester, the Group now operates from five sites, including four in Lancashire, which generate revenues totalling c.16% of the £1.7bn UK retail tissue market.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NORUPUBPMUPGGAQ
UK 100

Latest directors dealings